Evidence map›Paper›PMID 32540733›Full record

SynthesisDiabetes & metabolic syndrome

Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies.

Fernanda Farias Costa, Wilian Reis Rosário, Ana Cláudia Ribeiro Farias, Ramon Guimarães de Souza, Roberta Sabrine Duarte Gondim, Wermerson Assunção Barroso

Erratum issuedOpen access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetes & metabolic syndrome. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 72 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 1 pooled it
3.2field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 1 synthesis or guideline pooled it, 146 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Increased Incidence of Pancreatic Steatosis Detected Using Computed Tomography at Initial Diagnosis of Coronavirus Disease 2019.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2023
    Article
  17. Review
  18. Review
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Fernanda Farias CostaDepartment of Biomedicine, CEUMA University (UNICEUMA), R. Barão do Rio Branco, 100, Entroncamento, Imperatriz, MA, 65903-093, Brazil.
Wilian Reis RosárioDepartment of Biomedicine, CEUMA University (UNICEUMA), R. Barão do Rio Branco, 100, Entroncamento, Imperatriz, MA, 65903-093, Brazil.
Ana Cláudia Ribeiro FariasDepartment of Biomedicine, CEUMA University (UNICEUMA), R. Barão do Rio Branco, 100, Entroncamento, Imperatriz, MA, 65903-093, Brazil.
Ramon Guimarães de SouzaAmorim II Basic Health Unit, Conjunto Consolata, s/n, Amorim, Zé Doca, MA, 65365-000, Brazil.
Roberta Sabrine Duarte GondimDepartment of Pharmacy, Graduate Program in Health Sciences, Federal University of Maranhão, Campus do Bacanga, Av. dos Portugueses, s/n, Bacanga, São Luís, MA, 65080-040, Brazil.
Wermerson Assunção BarrosoDepartment of Biomedicine, CEUMA University (UNICEUMA), R. Barão do Rio Branco, 100, Entroncamento, Imperatriz, MA, 65903-093, Brazil. Electronic address: wermersonbarroso@yahoo.com.
Centro Universitário do Maranhão · BRUniversidade Federal do Maranhão · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

aimsMany patients with coronavirus disease 2019 (COVID-19) have comorbidities related to metabolic syndrome (MS) during the disease course. Its presence in different ethnicities and continents places MS as an important risk factor for COVID-19. Adequate understanding of the interplay between MS, COVID-19 and proposed therapies is required for optimum management of these patients.

methodsWe systematically searched the PubMed and Google Scholar databases until June 1st, 2020 and accessed the full text on COVID-19 and MS to prepare a narrative review on this topic.

resultsPatients with metabolic disorders like obesity, diabetes, cardiovascular and liver disease may face a higher risk of infection of COVID-19, greatly affecting the development and prognosis of the disease, being associated with significantly worse outcome in these patients. The proposed drugs that are in clinical trial for COVID-19 treatment must be carefully considered for clinical use, especially in patients with MS.

conclusionMS is a risk factor influencing the progression and prognosis of COVID-2019. The drugs currently evaluated for the infection treatment are promising but need further studies to prove their efficacy and safety, due to the adverse effects may be exacerbated by combination therapy or due to viral infection. The development of a vaccine for immunization is still the best long-term solution.

Indexed as

BetacoronavirusComorbidityCoronavirus InfectionsCOVID-19Disease ProgressionHumansMetabolic SyndromePandemicsPneumonia, ViralPrognosisRisk FactorsSARS-CoV-2Severity of Illness IndexCardiovascular diseaseCOVID-19DiabetesDrugsLiver diseaseMetabolic syndromeObesity

Identifiers

PMID32540733
PMCPMC7286828
OpenAlexW3035695825

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.